Simbol LLY | |
Simbol | LLY |
Simbol eToro | LLY |
MarketWatch | LLY |
Finviz | LLY |
Yahoo Finance | LLY |
Google Finance | LLY |
TradingView | LLY |
Investing.com | LLY |
Denumire | Eli Lilly & Co. |
Website | lilly.com |
Piața | NYSE |
ISIN | US5324571083 |
Sector | Health Technology |
Industrie | Pharmaceuticals Major |
Monedă | USD |
Preț | 832,5900 USD |
Capitalizare bursieră | 791,300 mld. USD |
P/E | 124,69 |
Beta | 0,5269 |
Dividend | 0,58% |
EPS | 6,6774 |
Profit anual | +87,06% |
Dată actualizare | 04.06.2024 |
Descriere |
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm's products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. The Oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. The Immunology products include Olumiant and Taltz. The Neuroscience products consist of Cymbalta, Emgality, Reyvow, and Zyprexa. The Other therapies include Bamlanivimab, Cialis, and Forteo. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN. |
Data | P/E | Beta | Capitalizare | Dividend | EPS | Profit anual | Preț |
15.11.2022 | 53,48 | 0,6469 | 338,320 | 1,10% | 6,6583 | +37,65% | $356,06 |
05.12.2022 | 56,28 | 0,6419 | 356,090 | 1,05% | 6,6583 | +52,12% | $374,76 |
14.02.2023 | 50,77 | 0,6287 | 332,940 | 1,16% | 6,9023 | +48,33% | $346,74 |
14.07.2023 | 72,62 | 0,5168 | 426,660 | 0,97% | 6,1893 | +39,62% | $449,46 |
03.11.2023 | 104,81 | 0,5336 | 539,020 | 0,80% | 5,4176 | +55,54% | $567,81 |
04.06.2024 | 124,69 | 0,5269 | 791,300 | 0,58% | 6,6774 | +87,06% | $832,59 |